Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene
AssigneesGenox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
InventorsRyoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
Life of this patent
Estimating the term…
Abstract
Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
Claims4
A method of testing for the remission stage of atopic dermatitis that is associated with a decrease in eosinophil cell number in a test subject having atopic dermatitis, said method comprising the steps of:
- (a) measuring the expression level of the NOR-1 gene in the eosinophil cells of the test subject having atopic dermatitis;
- and
- (b) comparing the expression level measured with the expression level of the NOR-1 gene in the eosinophil cells of the test subject during the exacerbation stage of atopic dermatitis,
- wherein the remission stage of atopic dermatitis that is associated with a decrease in eosinophil cell number is indicated by an increase in the level of NOR-1 gene expression in the eosinophil cells of the test subject having atopic dermatitis as compared with that in the eosinophil cells of the test subject during the exacerbation stage of atopic dermatitis.
A method of assessing the effect of a therapy on an individual in the exacerbation stage of atopic dermatitis comprising:
- (a) measuring the expression level of the NOR-1 gene in the eosinophil cells of the individual before and after the therapy;
- (b) comparing the expression level of the NOR-1 gene measured before the therapy to that measured after the therapy;
- and
- (c) determining whether the test subject has had a decrease in eosinophil cell number after the therapy,
- wherein an increase in the NOR-1 gene expression level and a decrease in eosinophil cell number after the therapy compared to that before the therapy indicate that the therapy has been effective.
Dependencies are inferred from the claim text.